Johnson & Johnson (NYSE:JNJ) Shares Acquired by Klingman & Associates LLC

Posted by Defense World Staff on May 2nd, 2023

Klingman & Associates LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,515 shares of the company’s stock after acquiring an additional 254 shares during the period. Klingman & Associates LLC’s holdings in Johnson & Johnson were worth $3,094,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Glassy Mountain Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson during the third quarter valued at approximately $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC grew its stake in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.1 %

Shares of NYSE JNJ opened at $163.60 on Tuesday. The business’s fifty day moving average price is $157.86 and its 200-day moving average price is $167.04. The stock has a market capitalization of $426.06 billion, a PE ratio of 34.23, a P/E/G ratio of 2.78 and a beta of 0.53. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.67 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 94.56%.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on JNJ. Raymond James cut their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. StockNews.com began coverage on Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, Atlantic Securities lowered their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.